Natural history of curatively resected stage IB-IIIA EGFR mutation (+) NSCLC: Clinicopathologic and molecular prognostic factors (ROOT-EGFR-ADJ).

被引：0
|
作者：
Jung, Hyun Ae
Jeon, Yeong Jeong
Kim, Jhingook
Park, Sehhoon
Sun, Jong-Mu
Lee, Se-Hoon
Ahn, Jin Seok
Ahn, Myung-Ju
Park, Keunchil
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Thorac & Cardiovasc Surg, Seoul, South Korea
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Thorac Surg, Seoul, South Korea
[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.8529
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8529
引用
收藏
页数：3
相关论文
共 41 条
  • [1] EGFR mutation (EGFRm) prevalence and mortality in patients with stage IB-IIIA NSCLC: A cohort study in Denmark
    Jakobsen, E.
    Taylor, A.
    Ehrenstein, V.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S730 - S731
  • [2] Results of molecular pathological Studies (NGS) in curatively operated Patients with Stage IB-IIIA NSCLC
    Kurz, S.
    Olive, E.
    Zaatar, M.
    Leschber, G.
    Grohe, C.
    PNEUMOLOGIE, 2022, 76 : S79 - S79
  • [3] Real-world outcomes in resected stage IB-IIIA EGFR mutated NSCLC in Canada: Analysis from the POTENT study
    Kuruvilla, M. S.
    Syed, I.
    Gwadry-Sridhar, F.
    Sachdeva, R.
    Pencz, A.
    Zhan, L.
    Hueniken, K.
    Patel, D.
    Balaratnam, K.
    Khan, K.
    Grant, B.
    Sheffield, B.
    Noy, S.
    Singh, K. P.
    Liu, L.
    Ralibuz-Zaman, M.
    Davis, B.
    Moldaver, D.
    Shanahan, M.
    Cheema, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S931 - S932
  • [4] Prevalence, Treatment Patterns and Long-Term Clinical Outcomes of Patients with EGFR Positive Resected Stage IB-IIIA NSCLC
    Schmid, S.
    Garcia, M.
    Hueniken, K.
    Balaratnam, K.
    Patel, D.
    Zhan, L.
    Brown, M. C.
    Sacher, A.
    Bradbury, P.
    Leighl, N.
    Shepherd, F. A.
    Liu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S945 - S945
  • [5] Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC)
    John, Tom
    Grohe, Christian
    Goldman, Jonathan W.
    Kato, Terufumi
    Laktionov, Konstantin K.
    Bonanno, Laura
    Tiseo, Marcello
    Majem, Margarita
    Domine, Manuel, Sr.
    Ahn, Myung-Ju
    Perol, Maurice
    Hartmaier, Ryan
    Robichaux, Jacqulyne
    Bhetariya, Preetida
    Markovets, Aleksandra
    Rukazenkov, Yuri
    Muldoon, Caitlin
    Herbst, Roy S.
    Tsuboi, Masahiro
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] HRQoL with Adjuvant Aumolertinib in Patients with Resected Stage IB-IIIA EGFR Mutant Non Small Cell Lung Cancer
    Hu, W.
    Mao, Z.
    Cheng, N.
    Huang, J.
    Tang, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S563 - S564
  • [7] Osimertinib as adjuvant therapy in patients with stage IB-IIIA EGFR mutation-positive (EGFRm) NSCLC after complete tumour resection: ADAURA
    John, Thomas
    Herbst, Roy
    Tsuboi, Masahiro
    Grohe, Christian
    Majem, Margarita
    Goldman, Jonathan W.
    Kim, Sang-We
    Marmol, Dominika
    Rukazenkov, Yuri
    Wu, Yi-Long
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 69 - 70
  • [8] Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA
    Grohe, C.
    Herbst, R. S.
    Tsuboi, M.
    John, T.
    Majem, M.
    Goldman, J. W.
    Kim, S. -W.
    Marmol, D.
    Rukazenkov, Y.
    Wu, Y. -L.
    Engel-Riedel, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 138 - 138
  • [9] Frequency of EGFR (epidermal Growth Factor Receptor) Mutations in Stage IB-IIIA NSCLC after complete Tumour Resection
    Rittmeyer, A.
    Tsuboi, M.
    Herbst, R. S.
    John, T.
    Majem, M.
    Goldman, J.
    Kim, S. W.
    Yu, C. J.
    Miziara, J. E. A.
    Novello, S.
    Urban, D.
    Akewanlop, C.
    Ozturk, A.
    Quang, B., V
    Kowalski, D.
    Marmol, D.
    Marotti, M.
    Laus, G.
    Wu, Y. L.
    Engel-Riedel, W.
    PNEUMOLOGIE, 2020, 74 : S131 - S131
  • [10] Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
    Brazel, Danielle
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2022, 13 : 47 - 52
12345